Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

Dublin, April 23, 2025 (GLOBE NEWSWIRE) -- The "Sorafenib Market Report 2025" has been added to ResearchAndMarkets.com's offering. This Sorafenib market report provides a comprehensive analysis of ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

The approval is based on the results from the CheckMate-9DW trial, in which 85 percent of patients in the comparator arm were treated with lenvatinib and 15 percent were treated with sorafenib ...